{
    "root": "727913f6-9542-4a2d-9318-4b7ff521bffd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Naproxen",
    "value": "20250320",
    "ingredients": [
        {
            "name": "NAPROXEN",
            "code": "57Y76R9ATQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7476"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        }
    ],
    "indications": {
        "text": "naproxen tablets naproxen sodium tablets indicated : relief signs symptoms : \u2022rheumatoid arthritis \u2022osteoarthritis \u2022ankylosing spondylitis \u2022polyarticular juvenile idiopathic arthritis naproxen tablets naproxen sodium tablets also indicated : relief signs symptoms : \u2022tendonitis \u2022bursitis \u2022acute gout management : \u2022pain \u2022primary dysmenorrhea",
        "doid_entities": [
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) rheumatoid arthritis , osteoarthritis , ankylosing spondylitis naproxen tablets 250 mg ( one-half tablet ) 500 mg twice daily naproxen sodium tablets 275 mg ( one-half tablet ) 550 mg twice daily dose may adjusted depending response patient . patients tolerate lower doses well , dose may increased naproxen 1500 mg/ day 6 months . polyarticular juvenile idiopathic arthritis naproxen tablets may allow flexible dose titration needed pediatric patients polyarticular juvenile idiopathic arthritis . liquid formulation may appropriate . recommended total daily dose naproxen approximately 10 mg/kg given 2 divided doses . dosing naproxen tablets appropriate children weighing less 50 kilograms . management pain , primary dysmenorrhea , acute tendonitis bursitis recommended starting dose 550 mg naproxen sodium naproxen sodium tablets followed 550 mg every 12 hours 275 mg every 6 8 hours required . initial total daily dose exceed 1375 mg naproxen sodium . thereafter , total daily dose exceed 1100 mg naproxen sodium . naproxen sodium tablets recommended management acute painful conditions prompt onset pain relief desired . acute gout recommended starting dose 750 mg naproxen tablets followed 250 mg every 8 hours attack subsided . naproxen sodium tablets may also used starting dose 825 mg followed 275 mg every 8 hours .",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "bursitis (DOID:2965)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2965"
            },
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute tendonitis bursitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "warningsAndPrecautions": "naproxen tablets , usp 375 mg : oval , light orange colored , biconvex , uncoated tablets , engraved \u2018 g 32 \u2019 one side \u2018 375 \u2019 side . packaged light-resistant bottles 100 500. bottles 20 , ndc 68788-8844-2 bottles 30 , ndc 68788-8844-3 bottles 60 , ndc 68788-8844-6 bottles 90 , ndc 68788-8844-9 bottles 100 , ndc 68788-8844-1 bottles 120 , ndc 68788-8844-8 store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . dispense well-closed containers .",
    "adverseReactions": "naproxen tablets naproxen sodium tablets contraindicated following patients : \u2022known hypersensitivity ( e.g . , anaphylactic serious skin ) naproxen components product [ ( 5.7 , 5.9 ) ] \u2022history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.7 , 5.8 ) ] \u2022in setting coronary artery bypass graft ( cabg ) surgery [ ( 5.1 ) ]",
    "indications_original": "Naproxen tablets and naproxen sodium tablets are indicated for:\n                  the relief of the signs and symptoms of:\n                  \n                     \n                        \u2022rheumatoid arthritis\n                     \n                        \u2022osteoarthritis\n                     \n                        \u2022ankylosing spondylitis\n                     \n                        \u2022Polyarticular Juvenile Idiopathic Arthritis \n                  \n                  Naproxen tablets and naproxen sodium tablets are also indicated for:\n                  the relief of signs and symptoms of:\n                  \n                     \n                        \u2022tendonitis\n                     \n                        \u2022bursitis\n                     \n                        \u2022acute gout\n                  \n                  the management of:\n                  \n                     \n                        \u2022pain\n                     \n                        \u2022primary dysmenorrhea",
    "contraindications_original": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis Naproxen tablets 250 mg (one-half tablet) 500 mg twice daily Naproxen sodium tablets 275 mg (one-half tablet) 550 mg twice daily The dose may be adjusted up or down depending on the clinical response of the patient. In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/ day for up to 6 months. Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets may not allow for the flexible dose titration needed in pediatric patients with polyarticular juvenile idiopathic arthritis. A liquid formulation may be more appropriate. Recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses. Dosing with naproxen tablets is not appropriate for children weighing less than 50 kilograms. Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis Recommended starting dose 550 mg of naproxen sodium as naproxen sodium tablets followed by 550 mg every 12 hours or 275 mg every 6 to 8 hours as required. The initial total daily dose should not exceed 1375 mg of naproxen sodium. Thereafter, the total daily dose should not exceed 1100 mg of naproxen sodium. Naproxen sodium tablets are recommended for the management of acute painful conditions when prompt onset of pain relief is desired. Acute Gout Recommended starting dose 750 mg of naproxen tablets followed by 250 mg every 8 hours until the attack has subsided. Naproxen sodium tablets may also be used at a starting dose of 825 mg followed by 275 mg every 8 hours.",
    "warningsAndPrecautions_original": "Naproxen Tablets, USP 375 mg: oval, light orange colored, biconvex, uncoated tablets, engraved with \u2018G 32\u2019 on one side and \u2018375\u2019 on the other side. Packaged in light-resistant bottles of 100 and 500.\n                  Bottles of 20, NDC 68788-8844-2\n                  Bottles of 30, NDC 68788-8844-3\n                  Bottles of 60, NDC 68788-8844-6\n                  Bottles of 90, NDC 68788-8844-9\n                  Bottles of 100, NDC 68788-8844-1\n                  Bottles of 120, NDC 68788-8844-8\n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Dispense in well-closed containers.",
    "adverseReactions_original": "Naproxen tablets and naproxen sodium tablets are contraindicated in the following patients:\n                  \n                     \n                        \u2022Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see Warnings and Precautions (5.7, 5.9)]\n                     \n                        \u2022History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.7, 5.8)]\n                     \n                        \u2022In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1)]",
    "drug": [
        {
            "name": "Naproxen",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7476"
        }
    ]
}